Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells

Journal of Nanobiotechnology

Volumn 13, Issue 1, 2015, Pages

  Kwak, Tae Won ^a   Kim, Do Hyung ^b   Jeong, Young Il ^a   Kang, Dae Hwan ^a,c  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Pusan National University Yangsan Hospital   (South Korea)

Author keywords

Block copolymer; Cancer chemotherapy; Cholangiocarcinoma; Drug targeting; Nanoparticles; Poly(dl lactide co glycolide); Vorinostat

Indexed keywords

ACETYLATION; BLOCK COPOLYMERS; CELLS; CHEMOTHERAPY; CYTOLOGY; DISEASES; ETHYLENE; ETHYLENE GLYCOL; INFRARED DEVICES; MOLECULAR IMAGING; TUMORS;

CANCER CHEMOTHERAPY; CHOLANGIOCARCINOMA; DRUG-TARGETING; POLY(DL-LACTIDE-COGLYCOLIDE); VORINOSTAT;

NANOPARTICLES;

CASPASE 3; HISTONE DEACETYLASE; HISTONE H3; MACROGOL; NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYGLACTIN; PROTEIN P21; PROTEIN P53; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHOLANGIOCARCINOMA CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; ENZYME INHIBITION; ENZYME REPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; CHEMISTRY; CHOLANGIOCARCINOMA; DRUG SCREENING; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE; WESTERN BLOTTING; X RAY DIFFRACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; FLUORESCENCE; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; MICE; NANOPARTICLES; PARTICLE SIZE; X-RAY DIFFRACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942259173     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-015-0122-4     Document Type: Article

References (50)

1. Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilidehydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer. 2006;95:S2-6.
2. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilidehydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem. 2006;281:5612-22.
3. Doi T, Hamaguchi T, Shirao K, Chin K, Hatake K, Noguchi K, et al. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int J Clin Oncol. 2013;18:87-95.
4. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, et al. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One. 2011;6:e24662.
5. Jin JS, Tsao TY, Sun PC, Yu CP, Tzao C. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. Pathol Oncol Res. 2012;18:713-20.
6. Chinnaiyan P, Chowdhary S, Potthast L, Prabhu A, Tsai YY, Sarcar B, et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol. 2012;14:93-100.
7. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, et al. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 2012;132:1063-72.
8. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy. 2010;6:1057-65.
9. Kwak TW, Kim do H, Chung CW, Lee HM, Kim CH, Jeong YI, et al. Synergistic anticancer effects of vorinostat and epigallocatechin-3-gallate against HuCC-T1 human cholangiocarcinoma cells. Evid Based Complement Altern Med. 2013;2013:185158.
10. Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. Am J Roentgenol. 2003;181:819-27.
11. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806-13.
12. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41:5-15.
13. Ciombor KK, Goff LW. Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol. 2013;11:28-34.
14. Brunner TB, Eccles CL. Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol. 2010;186:672-80.
15. Skipworth JR, Olde Damink SW, Imber C, Bridgewater J, Pereira SP, Malagó M. Surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol Ther. 2011;34:1063-78.
16. Rizvi S, Gores GJ. Pathogenesis, diagnosis and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215-29.
17. Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, et al. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer. 2010;116:2208-14.
18. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, et al. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer. 2006;106:1339-46.
19. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-81.
20. Leong E, Chen WW, Ng E, Van Hazel G, Mitchell A, Spry N. Outcomes from combined chemoradiotherapy in unresectable and locally advanced resected cholangiocarcinoma. J Gastrointest Cancer. 2012;43:50-5.
21. Furuse J, Okusaka T. Targeted therapy for biliary tract cancer. Cancers (Basel). 2011;3:2243-54.
22. Braga HJ, Imam K, Bluemke DA. MR imaging of intrahepatic cholangiocarcinoma: use of ferumoxides for lesion localization and extension. Am J Roentgenol. 2011;177:111-4.
23. Lee Y, Lee JS, Kim CM, Jeong JY, Choi JI, Kim MJ. Area of paradoxical signal drop after the administration of superparamagnetic iron oxide on the T2-weighted image of a patient with lymphangitic metastasis of the liver. Magn Reson Imaging. 2008;26:577-82.
24. Tang T, Zheng JW, Chen B, Li H, Li X, Xue KY, et al. Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int. 2007;6:303-7.
25. Towata T, Komizu Y, Kariya R, Suzu S, Matsumoto Y, Kobayashi N, et al. Hybrid liposomes inhibit the growth of cholangiocarcinoma by induction of cell cycle arrest in G1 phase. Bioorg Med Chem Lett. 2010;20:3680-2.
26. Chung KD, Jeong YI, Chung CW, Kim do H, Kang DH. Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells. Int J Pharm. 2012;422:454-61.
27. Hwang JH, Choi CW, Kim do HW, Kim H, Kwak TW, Lee HM, et al. Dextran-b-poly(l-histidine) copolymer nanoparticles for pH-responsive drug delivery to tumor cells. Int J Nanomedicine. 2013;8:3197-207.
28. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600-3.
29. Oh JK. Polylactide (PLA)-based amphiphilic block copolymers: synthesis, self-assembly and biomedical applications. Soft Matter. 2011;7:5096-108.
30. Morine Y, Shimada M, Iwahashi S, Utsunomiya T, Imura S, Ikemoto T, et al. Role of histone deacetylase expression in intrahepatic cholangiocarcinoma. Surgery. 2012;151:412-9.
31. Sun WJ, Zhou X, Zheng JH, Lu MD, Nie JY, Yang XJ, et al. Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis. Acta Biochim Biophys Sin (Shanghai). 2012;44:80-91.
32. Boonjaraspinyo S, Boonmars T, Kaewkes S, Laummaunwai P, Pinlaor S, Loilome W, et al. Down-regulated expression of HSP70 in correlation with clinicopathology of cholangiocarcinoma. Pathol Oncol Res. 2012;18:227-37.
33. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9:139-48.
34. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280:168-76.
35. Fang JY. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers. J Gastroenterol Hepatol. 2005;20:988-94.
36. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541-52.
37. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2012;13:1-13.
38. Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X, et al. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene. 2013;32:599-609.
39. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 2011;18:1904-13.
40. Chen YX, Fang JY, Zhu HY, Lu R, Cheng ZH, Qiu DK. Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. World J Gastroenterol. 2004;10:2643-6.
41. Said TK, Moraes RCB, Sinha R, Medina D. Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. Breast Cancer Res. 2001;3:122-33.
42. Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T, Luciano A, de Ruggiero I, Bruzzese F, Avallone A, Arra C, Budillon A. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br J Cancer. 2010;103:1680-91.
43. Wang EC, Min Y, Palm RC, Fiordalisi JJ, Wagner KT, Hyder N, Cox AD, Caster JM, Tian X, Wang AZ. Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials. 2015;51:208-15.
44. Li J, Gong C, Feng X, Zhou X, Xu X, Xie L, et al. Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts. PLoS One. 2012;7:e33860.
45. Mohamed EA, Zhao Y, Meshali MM, Remsberg CM, Borg TM, Foda AM, et al. Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(dl-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. J Pharm Sci. 2012;101:3787-98.
46. Kim JY, Shim G, Choi HW, Park J, Chung SW, Kim S, et al. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials. 2012;33:4424-30.
47. Thomas MB. Systemic and targeted therapy for biliary tract tumors and primary liver tumors. Surg Oncol Clin N Am. 2014;23:369-81.
48. Park W, Park SJ, Na K. The controlled photoactivity of nanoparticles derived from ionic interactions between a water soluble polymeric photosensitizer and polysaccharide quencher. Biomaterials. 2011;32:8261-70.
49. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-84.
50. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11:812-8.